Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model

Jing Wang1, Jihong Lin1, Ulrike Kaiser1

  • 15th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Acta Diabetologica
|January 11, 2017
PubMed
Abstract

Insights

Macrophage migration inhibitory factor (MIF) promotes retinal neovascularization in proliferative diabetic retinopathy. Inhibiting MIF reduces pathological angiogenesis by affecting VEGF, EPCs, and inflammation.

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Immunology

Background:

  • Proliferative diabetic retinopathy is characterized by ischemia-induced neovascularization.
  • Macrophage migration inhibitory factor (MIF) is elevated in proliferative diabetic retinopathy and has proangiogenic properties.

Purpose of the Study:

  • To investigate the role of MIF in ischemia-induced retinal neovascularization.
  • To determine if MIF contributes to pathological angiogenesis in a mouse model.

Main Methods:

  • Mice were subjected to a retinopathy of prematurity (ROP) model.
  • Vessel regrowth and neovascularization were assessed using immunofluorescence and PAS staining.
  • Gene expression, endothelial progenitor cell (EPC) recruitment, and microglial activation were analyzed.

Main Results:

  • MIF deficiency significantly increased vascular obliteration and reduced preretinal angiogenesis.
  • VEGF expression in Müller cells was reduced in MIF-knockout mice.
  • MIF absence decreased proangiogenic/proinflammatory factors, reduced EPCs, and inhibited microglial activation.

Conclusions:

  • MIF exhibits proangiogenic and proinflammatory roles in retinal neovascularization.
  • MIF's proangiogenic function is linked to VEGF, erythropoietin, EPC recruitment, and inflammation.
  • MIF is a potential therapeutic target for pathological angiogenesis in proliferative retinopathy.

Related Concept Videos